Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003119428 | SCV003790752 | pathogenic | Glycogen storage disease, type II | 2021-12-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the GAA protein in which other variant(s) (p.Leu552Pro) have been determined to be pathogenic (PMID: 14695532, 17616415, 18607768, 19588081, 20638881, 24158270, 25681614, 27666774). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 369943). This variant has not been reported in the literature in individuals affected with GAA-related conditions. This variant results in the deletion of exons 12-18 and part of exon 19 (c.1636+460_2672del) of the GAA gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). |